Maze Therapeutics, Inc. 4

CSBO Atul Dandekar of Maze Therapeutics, Inc. exercised options for 7,500 shares at $10.42 and sold 7,500 Common Stock shares around $27.3–27.9 on July 29, 2026 under a Rule 10b5-1 plan.

On July 29, 2026, Maze Therapeutics, Inc. CSBO Atul Dandekar exercised a stock option for 7,500 shares of Common Stock at $10.42 per share and immediately sold 7,500 shares in two open-market transactions under a Rule 10b5-1 trading plan. The sale consisted of 7,100 shares at a weighted average price of $27.3064 (within a range of $26.81 to $27.79) and 400 shares at a weighted average price of $27.8900 (within a range of $27.81 to $27.96), implying gross sale proceeds of roughly $204,800 against an option exercise cost of about $78,150. Following these transactions, which represent a sell-to-cover or monetization of vested options rather than a direct open-market purchase, Dandekar’s direct ownership in Maze Therapeutics stands at 26,250 shares of Common Stock, with an estimated value of approximately $715,000 based on the reported sale prices.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

4

Source Type

fda

Accession

0002050167-26-000019

Alert Tier

6